eprintid: 10093454
rev_number: 19
eprint_status: archive
userid: 608
dir: disk0/10/09/34/54
datestamp: 2020-03-17 12:52:21
lastmod: 2021-12-17 22:59:38
status_changed: 2020-03-17 12:52:21
type: article
metadata_visibility: show
creators_name: Cox, E
creators_name: Saramago, P
creators_name: Kelly, J
creators_name: Porta, N
creators_name: Hall, E
creators_name: Tan, WS
creators_name: Sculpher, M
creators_name: Soares, M
title: Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial
ispublished: inpress
divisions: UCL
divisions: B02
divisions: C10
divisions: D16
divisions: G88
keywords: Cost, HRQoL, NMIBC, QALY, RCT
note: © 2019 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
abstract: BACKGROUND: Limited evidence exists regarding the cost and health-related quality of life (HRQoL) effects of non-muscle-invasive bladder cancer (NMIBC) recurrence and progression to muscle-invasive bladder cancer (MIBC). We examined these effects using evidence from a recent randomized control trial. MATERIAL AND METHODS: The costs and HRQoL associated with bladder cancer were assessed using data from the BOXIT trial (bladder COX-2 inhibition trial; n = 472). The cost and HRQoL effects from clinical events were estimated using generalized estimating equations. The costs were derived from the recorded resource usage and UK unit costs. HRQoL was assessed using the EQ-5D-3L and reported UK preference tariffs. The events were categorized using the TMN classification. RESULTS: Cases of grade 3 recurrence and progression were associated with statistically significant HRQoL decrements (-0.08; 95% confidence interval [CI], -0.13 to -0.03; and -0.10; 95% CI, -0.17 to -0.03, respectively). The 3-year average cost per NMIBC patient was estimated at £8735 (95% CI, 8325-9145). Cases of grade 1, 2, and 3 recurrence were associated with annual cost effects of £1218 (95% CI, 403-2033), £1677 (95% CI, 920-2433), and £3957 (95% CI, 2332-5583), respectively. Progression to MIBC was associated with an average increase in costs of £5407 (95% CI, 2663-8152). CONCLUSION: Evidence from the BOXIT trial suggests that patients with NMIBC will both experience decrements in HRQoL and incur significant costs, especially in the event of a grade 3 recurrence or a progression to MIBC.
date: 2019-12-14
date_type: published
official_url: https://doi.org/10.1016/j.clgc.2019.12.004
oa_status: green
full_text_type: pub
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 1732178
doi: 10.1016/j.clgc.2019.12.004
pii: S1558-7673(19)30377-5
lyricists_name: Kelly, John
lyricists_name: Tan, Wei Shen
lyricists_id: JDKEL61
lyricists_id: WSTAN49
actors_name: Flynn, Bernadette
actors_id: BFFLY94
actors_role: owner
full_text_status: public
publication: Clinical Genitourinary Cancer
event_location: United States
citation:        Cox, E;    Saramago, P;    Kelly, J;    Porta, N;    Hall, E;    Tan, WS;    Sculpher, M;           Cox, E;  Saramago, P;  Kelly, J;  Porta, N;  Hall, E;  Tan, WS;  Sculpher, M;  Soares, M;   - view fewer <#>    (2019)    Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial.                   Clinical Genitourinary Cancer        10.1016/j.clgc.2019.12.004 <https://doi.org/10.1016/j.clgc.2019.12.004>.    (In press).    Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10093454/1/1-s2.0-S1558767319303775-main.pdf